STUDY OF PREECLAMPSIA IN PLACENTA, KIDNEY, AND HEPATIC DISEASES

PUTRI CAHAYA SITUMORANG, SYAFRUDIN ILYAS*
Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia.
Email: syafрудi6@usu.ac.id
Received: 06 May 2018, Revised and Accepted: 03 July 2018

ABSTRACT

Preeclampsia (PE) have a high risk of pregnancy disorder and can cause liver and kidney disease. PE is a dangerous disease in Indonesia with a high risk of cardiovascular death. PE has biomarkers such as proteinuria, blood pressure, diastolic test, renin-angiotensin system, adipsin, calcium/creatinine (Cr) ratio, albumin/Cr ratio, and uric acid. Apoptosis occurs in the placenta’s PE, where trophoblasts invade and overrule the uterine spiral artery in the epidermal growth factor signaling system, and the expression of miRNA in PE is targeting genes in a variety of pathological processes can cause kidney and hepatic disease. In this review, we will discuss the role of HSP, mRNA, Immunology cell and the risk of kidney and hepatic disease of patient of Preeclampsia.

Keyword: Preeclampsia, Placenta, Kidney diseases, Hepatic diseases, mRNA.

© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.27540.

INTRODUCTION

Preeclampsia (PE) is a dangerous and potentially life-threatening disease for the mother and fetus which occurs uniquely in Indonesia, so the improvement of the standard diagnostic approach with complement is very important for this problem and development of future treatment strategies [1,2]. According to Survei Demografi dan Kesehatan Indonesia in 2007, PE contributes to 2.4% of maternal mortality in Indonesia, makes it second cause of maternal death in Indonesia [3]. International non-governmental organization Forum on Indonesian Development states that Indonesia is a country in Southeast Asia with the highest maternal mortality of 359/100.000 births [4].

Chronic hypertension pre-pregnancy can lead to developmental rates of severe hypertension so that babies are premature and small [5]. One of the characteristics of PE is the syncytial node-forming process, the shedding of the syncytial aggregate, and the appearance of placental microparticles in the maternal and contributes to maternal vascular injury [6]. Strong evidence supports the involvement of deficient trophoblast survival, inadequate endothelial invasion, endothelial cell dysfunction, and a systemic maternal inflammatory response [7,8]. Failure of trophoblast invasion inhibits decidualization leading to poor placental blood supply in maternal vessels which further generates placental ischemia and apoptosis [9]. PE can cause diseases of the liver and kidneys. Those diseases may not be initiated by pregnancy, but interfere strongly with pregnancy. Exact diagnosis is therefore of high clinical relevance [10]. Not just in science, there is a direct and indirect relationship regarding the empowerment of PE prevention in pregnant women through the theory of social capital to Indonesia society [11].

BIOMARKER IN PE

PE may be characterized by hypertension and proteinuria after 20 weeks of pregnancy and a change in the angiogenic factor [12,13]. Detected proteinuria can be used dipstick test with urine sample concentration with creatinine (Cr) is higher [14]. Massive Urinary Protein also has the potential to be associated with more severe clinical manifestations of PE [15]. Significantly, isolated gestational (IG) proteinuria was also a risk factor for PE and ICP-PE accounted for most (20%) of all PE [16]. Women who have higher levels of urea nitrogen in the blood have a higher incidence of PE; premature labor (women with kidney disease with p<0.001), 8/35 (23%); premature rupture of membranes; and intrauterine growth restriction [17-19]. Urinary protein, adipsin, was found to increase significantly and the ratio of Cr to adipsin correlated with urine protein, for 24 h in 124 patients combined with elevated diastolic blood pressure (≥90 mm Hg) [20]. It is important to know that increased activity of a local renin-angiotensin system (RAS) in the kidney, correlates with high blood pressure, and proteinuria in PE [21]. Oral labetalol is more efficacious and important for effective control of blood pressure in PE [22]. Hypertension, proteinuria, and renal function resolved normally over an average period of 35.8 days and neurologic complications, pulmonary edema, and multiple organ failure can be a cause of death [23]. No woman with protein: Cr ratio <18 mg/mM (n=20) had significant proteinuria, but between 18 and 60 mg/mM [24]. To assess the effectiveness of the calcium/creatinine ratio (CCR) as a diagnostic test for PE predicted, CCR at 0.04 in spot urine samples was a good test, as a screening test on all asymptomatic pregnant women [25]. The first albumin/creatinine ratio (ACR), for urine samples was a good test, as a screening test on all asymptomatic pregnant women [26].

Proteinuria-onset PE is associated with an increased adverse risk of PE with the onset of hypertension [27]. Hypertension and proteinuria are very common outside the postpartum period in Cameroonian women with severe PE and eclampsia [28]. In severe PE with proteinuria >3 g/L showed that the amount of proteinuria is not associated with severe PE, although proteinuria is detected, prematurity may occur [29]. Serum cytoglobin was significantly more effective and higher in patients with early-onset preeclampsia (EO-PE) and slow onset of preeclampsia (LOPE), compared with healthy pregnant women [30]. Uric acid with proteinuria can identify perinatal risk with high risk with gestational hypertension in women [31]. However, serum uric acid will increase after presentation of clinical symptoms of PE and cannot be a biomarker [32].

ROLE OF HEAT SHOCK PROTEIN (HSP) IN PREECLAMPSIA

HSPs play an important role in the maintenance of cellular homeostasis, where these proteins constitute about 5–10% of the total protein of all normal cells and mediate protein assembly and proper intracellular localization [33]. HSP20 is widely expressed under normal physiological conditions and plays an important role in the dilution of blood vessels and the collection of platelet suppression and as a marker for predicting the onset of PE or severity with decline in the chorionic plate resistance artery and in serum female PE [34]. HSP27 was found to be a translation...
initiation and signal transducer, transcription activator-3 (STAT3) level administrator, because HSP27 is a key protein during the development of placenta and differentiation of trophoblast cells, STAT3, and eukaryotic initiation factor of eukaryotic 4E is involved in regulating the differentiation/migration of extracellular trophoblast cells [35]. Upregulation of Hsp27 is a common phenomenon in pregnancy that is affected with PTB and PPROM. Downregulation of HSP70 and HSPBP1 also represents the unique feature of PPROM [36]. HSs can be induced in cells as a protective mechanism and play a role in PE [37].

HSP70 is one factor that can mediate the effects of cytotoxic, ant apoptotic, and immune regulation, HSP70 serum concentrations were significantly higher in patients with PE than in the control group. Therefore, HSP70 may be identified as a diagnostic factor [38]. Serum HSP70 plays a protective role in tissue damage and a higher liver stiffness value in patients with biliary atresia, so serum HSP70 and liver stiffness may serve as a non-invasive parameter [39]. HIF-1α and HSP70 have a close relationship with the origin and development of the disease for the diagnosis and treatment of the disease [40]. HSP70 and proliferation are associated with trophoblast cells and decidual cells in exhibiting highly proliferative activity, as demonstrated by PCNA immunohistochemistry, at the mid-gestational stage. However, the difference in the percentage of PCNA-positive cells observed in the final stages [41]. HSP70’s also protect cells from the proteotoxic stress associated with abnormal rapid proliferation, suppresses cell aging and provides resistance to stress-induced apoptosis including protection against cytostatic, drugs, and radiation therapy [42]. Recent data also showed that serum Hsp70 (HSPA1A) levels are elevated in diabetes mellitus types 1 and 2. However, further research is needed to determine whether Hsp70 is a cause in the pathogenesis of gestational diabetes [43].

ROLE OF IMMUNOLOGY CELLS IN PE

The immunologic mechanism also plays an important role in the pathophysiology of PE. Helper T-Cell 17 (Th17) as a new subset of effector T-cells and plays an important role in host defense in extracellular pathogens, autoimmune, and inflammatory in PE such as recurrent spontaneous abortion (RSA) [44]. T regulatory cells (Treg cells, FoxP3 +) suppresses cytotoxic T-cells (CD8+) and responds to normal killer cells (NK) and increases immunological tolerance in the fetus [45]. Dendritic cells (DC) are also involved in the immune system, which regulates differentiation of Th17 and regulatory T-cells (Treg) participating in PE and RSA, but there is still a shortage in the intrathoracic cholesterol study of pregnancy (ICP) [46]. IL-17 and podocyte levels also had a positive association in serum and overexpression of microRNA-155 (miR-155) in PE patients, thus results in increased IL-17 production by CD4 + T-cells in vitro, and decreased nephrin expression in podocytes and apoptotic processes of podocytes [47]. In addition, high red cell distribution width can be a promising marker to predict low CD4 cell counts in HIV-positive reproductive women in antiretroviral therapy in PE women [40]. The effects of adiponectin on the cardiovascular system in hypertensive patients are believed to be partially mediated by activation of S’ active adenine monophosphate protein kinase and pathway cyclooxygenase-2, reduces endothelial cell apoptosis, promotes the production of nitric oxide, decreased activity in tumor necrosis factor-alpha (TNF-α), and prevents atherosclerotic proliferation and smooth muscle cell migration [49]. In addition, there is a consensus strategy to improve early detection and enrichment of pathogenic genes in PE such as HSP90, PAR2, CD247, and others, included in the first 1% of the prioritized list, so it needs to be explored further on the pathogenesis of PE through an experimental approach [50]. Activation of endothelial antibodies is also a marker of cardiovascular system dysfunction and endothelial dysfunction as well as severe pathology, with multiple organ failure manifestations, which is evidence of the relevance of this area of research to a large number of patients [51]. Detyrosination and tyrosination of tubulin are also important for the stability and dynamics of microtubules and significantly reduces the level of dety-tubulin in the placental biopsy, placental angiogenesis damage, and vascularization in cases of PE [52]. The implantation site macrophages comprised about 20% of the population leukocytes, and as a major mediator thereby increasing the expression of M-CSF, pro-inflammatory cytokines, IL-1b, or TNF-α, mainly through the NF-κB pathway signal to increase M-CSF expression in FTDGs, leading to M2 polarization of macrophages, and the phagocytic capacity of M2 macrophages is consistently improved, possibly through downregulation of SIRPα [53]. In gene levels, based on expression of 15 genes from C19MC, microRNAs (miR-512-5p, miR-515-5p, miR-516-5p, miR-517-5p, miR-518b, miR-518f-5p, miR-519a, miR-519d, miR-519e-5p, miR-520a-5p, miR-520h, miR-524-5p, miR-525, miR-526a, and miR-526b) were assessed in the placental tissue, miR-519a was found to be associated with severe PE. The longer the pregnancy-related disorder progresses, the wider the regulation of microRNAs decreases (miR-515-5p, miR-516b, miR-518f-5p, miR-519d, and miR-520h). Downregulation of some C19MC microRNAs is a common phenomenon that can cause PE. On the other hand, some C19MC microRNAs are only derived only on PE [54]. In Egyptian women, There is a significant association between VEGF C 405 G and VEGF C 2578 A gene polymorphisms. Thus, the screening for PE mutations for all Egyptian pregnant women in order to set up an appropriate method of prophylaxis against these pre-eclamptic disorders [55].

APOPTOSIS OF PLACENTA IN PE

The main cause of PE is the placenta in the presence of trophoblast tissue that can cause apoptosis [56]. In addition, toxic effects of carbon monoxide from tobacco can damage mitochondria in pregnant smokers, resulting in reduced birth weight [57]. Apoptosis in the placenta was found to increase in PE and associated with the activation of caspase-3 on the extrinsic pathway, then caspase-3 activation [58]. FasL expression was significantly less and Bcl-2 expression was significantly greater in villous trophoblasts due to increased apoptosis and the formation of a synthetic node combination by reducing Fasl. expression may be involved in the pathophysiology of the mechanism of PE [59]. Increased apoptotic signaling leads to reduced nutrient transport capacity, which triggers the release of vascular factors in the placenta, maternal vascular production response, and the fetus must PE. To cope with the stress, the main immunologic mechanism also plays an important role in the extracellular and intracellular processes and promote the fetus [60]. A danger signal in preeclampsia, that is, high mobility group box 1 that participates in various inflammatory processes and processes in the placenta [61]. Fetal developmental disorders cause antioxidant enzymes not able to cope with increased levels of oxidative stress, resulting in epithelial changes at the specific level of genes to transcribe antioxidant enzymes [62]. Teplotes which are the main type of small cells associated with signal transmission mechanisms in the regulation of fetal blood vessels in placenta PE can be damaged by oxidative stress and placental apoptosis of endothelial cells, and trophoblast cells [63]. For strong antioxidants, melatonin and indoleamine has utility in the treatment of PE, intruterine growth restriction, placental and fetal/reperfusion ischemia, etc [64].

Maintain a physiological balance between the proliferation of cytotrophoblast (CTB) with the placental win and apoptosis is very important because of increased oxidative stress and apoptosis in the pathological placenta is not balanced [65]. Impaired nitric oxide pathways and excessive stress on endoplasmic reticulum (ER) have been observed in the stress response and INOS that may be associated with increased apoptosis in the placenta of PE patients [66]. In HELLP syndrome, there is an increase in apoptosis, proliferation, and FAS ligand expression in the placenta compared with placentae PE and normal pregnancy [67]. One of the placental factors involved in triggering PE is trophoblast debris, which can pass the pathogen signals from the placenta to endothelial cells, where trophoblastic debris from the placenta of PE leads to endothelial cell activation [68]. Observation of trophoblast cells in the placenta can be done with Formalin-fixed paraffin-embedded (FFPE), observed with immunohistochemistry and calcycin, resulting in an increase in trophoblast cells in the placenta PE compared with normal trophoblast cells [69]. To determine cell apoptosis or cell fragments derived from CTB or syncytiotrophoblast, use E-cadherin staining together with markers for apoptosis [70].
During pregnancy, the subset of placental CTB differentiates into cells that aggressively invade the uterus and blood vessels [71]. The vasculosyncytial membrane (VSM) is a fetomaternal exchange when syncytiotrophoblast surrounds the terminal villi and makes close contact with the capillaries. The inverse relationship between the VSM and hypoxia in the fetus disrupts the syncrystal PE [72]. Increased apoptosis, CTB necrosis, and syncytiotrophoblast may compromise placental function, including nutrient transport and cause increased shedding syncytiotrophoblast extracellular vesicles (STBEV) in PE, but relaxin (pregnancy hormone) may improve [73]. The release of extracellular vesicles (EVs) by syncytiotrophoblast (STB) is an important mechanism, in which placental signaling to the mother is important in the formation, maintenance of a healthy pregnancy and provides a real-time reading of placental health [74]. After delivery of the placenta, the rapidly restored state is caused by growth factors vascular endothelial signals which are impaired [75,76]. However, with the administration of 1,25-dihydroxyvitamin D (1,25(OH)2D) during pregnancy reduces the adverse outcome of PE [77], Pomegranate juice can reduced oxidative stress on the placenta in vivo and in vitro induced by stimuli from trophoblast women PE [78]. A decreased enzymatic antioxidant capacity and increased oxidation in placental tissue from PE women, which may contribute to the pathogenesis of this complex disorder [79]. In the study, the presence of concentration nitric oxide in placenta PE was higher significantly than normal placenta. Hence, there was no significant difference caused by decrease markedly of ROS production [80].

The development of PE induced by apoptosis of trophoblast cells may decrease miR-34a which is an effective strategy for increasing apoptosis in the trophoblast cells [81]. Apoptosis in trophoblasts also invades and overhauls the uterine spiral artery in the signal system of epidermal growth factor signaling that regulates differentiation in trophoblasts [82]. The Wnt signaling pathway plays an important role in regulating trophoblast functions. Wnt signaling pathways were detected in the placenta in the third trimester, decreased placental expression of Wnt2, and increased placental expression of secreted frizzled-related protein 4 (SFRP4) [83]. Signaling is the function of the Wnt/β-catenin pathway in the placenta of PE is significantly inhibited, due to oxidative stress and apoptosis [84]. Excessive activation of the terminal pathway is associated with fetal growth restriction in preeclamptic women in the third trimester of human pregnancy [85]. In apoptosis, protein P53 is regulated in HUECs which triggers the capture of G1, then P21 expression increases, decreases the regulation of cyclin E expression, and CDK2-cyclin E complex. Increased regulation of P53 also activates the Bax gene, suppresses the Bcl-2 gene, BIMCS resulting increased ratio Bax/Bcl-2 ratio, and then activated caspase cascade, eventually apoptosis [86]. At the moment advances in biomarkers, therapies and genetic profiles are becoming an effective treatment in PE [87]. Potential biomarkers of this disease, such as activin A may lead to increased nodal expression and further increase Nodal/ALK7 signaling to induce apoptosis of the trophoblastic cells [88]. Low-dose aspirin is also widely used in preventing PE and reduces apoptosis caused by H2O2 reduces the ability of caspase-3 activation and TNF-α expression levels in PE [58]. New mitochondrial proteins such as mitofusin-2 (Mfn2) in the placenta are detected by qRT-PCR, indicating mitochondrial dysfunction, decreasing trophoblast cell viability, and contributing to the multifactorial pathogenesis mechanism of PE [89]. The important role of mitochondrial activity changes in the adaptive response to the development of PE, due to increased OPA1 mRNA and protein expression in the placenta [90]. Potential genes such as STOX1 and ACVR2A were also identified determining their causality in PE disorders [91]. In PE, male fetal placenta is associated with much higher expression of inflammation, hypoxia, and apoptosis than female fetal placenta but reduces the expression of pro-angiogenic markers [92].

Complementary system activation is also involved in PE pathologic processes, such as complementary 3a (C3a) that plays an important role in placentation abruption, regulate migration, and trophoblast angiogenesis and is also associated with maternal blood pressure and arterial stiffness [93]. Calreticulin (CRT) is also an important ER resident protein (ER) that participates in the intracellular regulation of Ca2 homeostasis, cell adhesion, and cell apoptosis [94]. Shedding of syncytiotrophoblast microparticles from the placenta to maternal blood occurs under normal circumstances of pregnancy and is enhanced during PE [95]. Placental on syncytiotrophoblast microvesicles (STBM) in the maternal circulation during normal pregnancy is significant in PE and STBM proteins are involved in immune responses, coagulation, oxidative stress, apoptosis, and lipid metabolism [96]. Injection of light into pregnant mice also induces placental apoptosis, small fetuses, PE, hypertension, and proteinuria where light functioning through 2 receptors induces the secretion of fms-like tyrosine kinase-1 and endothelin-1, 2 pathogenic factors in PE [97].

PLACENTAL MICRORNA EXPRESSION IN PE

MicroRNAs (miRNAs) have emerged as major regulators in the stability of gene expression involved in cell proliferation and apoptosis, whereas their expression may be altered in association with a variety of pathological disorders, such as in PE and preterm delivery [98]. There are Target genes of miRNAs, that participate in organ/system development (cardiovascular and reproductive system), immunologic dysfunction, cell adhesion, cell cycle, and signaling in PE [99]. MicroRNA (miRNA) is a small non-coding RNA which regulates gene expression through mRNA degradation and translational suppression. As a result, the expression of miR-210 is regulated in the placenta causing repression. Thus, miR-210 has a major effect on placental mitochondria [100]. Three miRNAs (miR-17-5p, miR-20a, and miR-20b) increased significantly in PE compared with normal placenta [101].

HEPATIC DISEASE IN PE

Liver disorders of PE may increased liver enzymes, low platelets (HELLP), acute fatty liver, hyperemesis gravidarum, intrahepatic cholestasis, and autoimmune liver [102]. Atypical hemolytic uraemic syndrome in a woman pregnant was when the given diagnosis of gestational hypertension, and hemolysis, elevated liver enzymes, and low platelet count (HELLP) also occurs in preeclampsia [103]. In terms of age, elderly gravidae (age ≥35 years) showed higher levels of urea and uric acid when compared with women <35 years, so increased age may increase the risk of impaired kidney and liver function [104]. Based on the Fibroscan results for 1–7 days postpartum, fibrosis was significantly higher in PE women (although within the normal range) [105]. Most of the causes of liver function impairment during the third trimester were hypertension, which induced pregnancy with HELLP syndrome (37%), acute fatty liver pregnancy (37%), and viral hepatitis (20%) [105,106]. In PE disorders, non-hypoxia is also a pathway that may be involved in angiogenic changes and abnormal metabolism in PE because defects in angiogenesis and mitochondrial function in the placenta contribute to the pathogenesis of PE, but the upstream regulator of this path is unknown [107]. Trophoblastic mitochondrial damage is a common terminal path, as it may cause different changes in lipid metabolism [108]. LD-Lc and HDLc isolated from PE indicating oxidative damage to lipids and proteins. Antioxidants are needed to reduce oxidative stress and induce damage in the vascular endothelium [109]. Selenium is an important constituent that acts as an antioxidant and has some possible metabolic function in terms of treating PE with a certain concentration [110]. Extra Virgin Olive Oil (EVOO), in the form of extra virgin, contains a rich function in terms of treating PE with a certain concentration [110]. Vitamin E (α-Tocopherol) is an antioxidant vitamin that participates in the reduction of lipid peroxidation. In terms of reducing PE, extra virgin olive oil (EVOO), rich in vitamin E reduces the level of oxidized low-density lipoprotein (OxLDL) in the maternal circulation during normal pregnancy [111]. The significant effect of EVOO on TGF-β expression in placenta and there was no positive strong relationship (r=0.494) as well as a very significant relationship (p<0.01) between TGF-β and the serum MDA [112].

On multivariate analysis, women with abnormal alanine aminotransferase level before pregnancy had a 1.21-fold increased risk of developing preeclampsia than those with normal alanine aminotransferase level before pregnancy [113]. Patients with intrahepatic cholestasis of pregnancy and elevated levels of alanine aminotransferase should be
followed up for perinatal normal results, so as to safeguard maternal and fetal safety [114]. Serum levels of liver fatty acid-binding proteins (LFABP) in PE women, correlated with the severity of PE, may be used to confirm the diagnosis [115]. HELLP syndrome can be predicted by elastasonography acoustic radiation force impulse (ARFI) [116]. For the diagnosis of HELLP syndrome, elevated levels of ET-1, M30, and Angs-1 and -2 appear as promising apoptotic-associated biomarkers where serum M30 levels have the benefit of being the most promising test for predictive or differential diagnosis of HELLP syndrome in PE patients [117]. D-dimers can also be as biomarkers in fibrin formation and degradation where levels were significantly increased in Sudanese women with PE, with hemostatic abnormalities [118].

Women who have non-alcoholic fatty liver (NAFLD) before delivery of the fetus, increase the risk of pregnancy adversely independently of body mass index and diabetes and should be monitored carefully during antenatal care [119]. Prenatal serum bilirubin, plasma fibrinogen levels, and platelet counts are the predictors of postpartum recovery in the acute fatty liver of pregnancy (AFLP) [120]. Chronic alcohol consumption without AFLD can lead to significant circulation increases, as an inflammatory marker and may result in downregulation of oxidative stress production [121]. In addition to acute fatty liver of pregnancy (AFLP), intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease in pregnancy that causes hepatobiliary and immune-mediated cancers and endothelial disease [122]. In Western India, Hepatitis E is the most common cause of liver disease in pregnant women resulting in maternal mortality, predicted with high MELD scores [123]. Two rare causes of hepatitis, especially fulminant (rare complications of the herpes simplex virus) such as HSV-1 and HSV-2 are comorbid in the same patient [124]. Pregnancy in women with cirrhosis of the liver, portal hypertension, or esophageal varices leads to worse pregnancy and may warrant closer antenatal monitoring and patient counseling [125]. Different levels of bile acid and carnitine circulation can be altered in patients with primary biliary cirrhosis (PBC) as potential biomarkers [126]. The circulating levels of different bile acids and carnitines can be changed in patients with primary biliary. Liver infarction is dangerous and complications associated with hemolysis, elevated liver enzymes, and ow platelet syndrome (HELLP), may cause cardiac arrest and fulminant liver failure [127]. Due to advances in obstetric and transplant medications, women with a history of liver transplants can have successful pregnancies. The transplanting process should have a relationship with maternal and fetal levels of high morbidity [128]. Liver transplantation also restores exual function and fertility as early as, a few months after transplantation [129].

KIDNEY DISEASE IN PE

Renal function monitoring appears to be relevant for PE, especially since albuminuria should be evaluated in postpartum and are classified at high risk for impaired renal function [130]. Podocytes play a role in the development of kidney damage and prevention of long-term complications of PE [131, 132]. The depletion of podocytes in the kidneys is associated with end-stage renal disease (ESKD). PE may also increase the risk of future ESKD [133]. The depletion of podocytes may also affect individuals with the APOL1 genotype against the risk of kidney disease in blacks [134]. Persistent proteinuria is the most important predictor of renal disease and sustained proteinuria, persistent hematuria, or renal function disorder after the postpartum period [135]. Proteinuria also results in the loss of fetuin-A, resulting in low molecular weight [136].

Renal disease and sustained proteinuria, persistent hematuria, or renal function disorder after the postpartum period [130]. Proteinuria also results in the loss of fetuin-A, resulting in low molecular weight [136].

However, PE is more common in renal donors [141]. Acute kidney injury (AKI) is a serious problem during pregnancy and understanding the physiological kidney adaptation during pregnancy is essential for early detection, diagnosis, and appropriate management to prevent obstetric complications [142]. In pregnant women with type I diabetes mellitus (T1DM) at increased PE risk, urine albumin examination should be performed to prevent kidney complications [143]. Giving serum containing gelatin-associated gelatinase (NGAL) can be correlated with renal infection in severe PE [144]. Tempol, a mimetic dismutase-antioxidant drug has been shown to weaken radical damage, exert beneficial effects on animal models of oxidative stress and hypertension, against chronic ischemic renal injury, and prevent renal dysfunction through antioxidants, vasodilators, and antihypertensive [145]. In addition, the plant-based diet should be limited, especially those containing proteins in PE patients, as it can control proteinuria in pregnant CKD women with segmental focal glomerulosclerosis [146].

PE is also associated with hypercoagulability, endothelial dysfunction, and inflammation, resulting in microparticles (MPs) in which microparticles of platelets (PMPs), endothelial cells (EMP), and leukocytes (LMPs) which are a method of knowing the presence of endothelial dysfunction and inflammation involved in the pathogenesis of PE [147]. Glomerular damage kidneys are common in PE and can be identified with tubular channels such as 1-microglobulin (A1M), retinol-binding protein (RBP), molecule-1 (KIM), C5b-9, metalloproteinase-2 (TIMP-2), and insulin growth factors binding protein-7 (IGFBP-7) [148]. Metalloproteinase-2 and IL-18 tissue inhibitors show that the kidneys have an increased inflammatory response during pregnancy and tubular epithelial tubular injury [149]. Biomarkers have also been found to differentiate CKD and PE, where the sflt-1 rate increases significantly compared to CKD and control [150]. Levels of sFlt-1/PIGF ratio in pregnancy-induced preeclampsia significantly decreased and down-regulation of nephrin is involved in L-NAME induced proteinuria [153]. Moleculaly recently, DNA-containing mitochondria with unmethylated CpG motifs and formyl peptides have been shown to damage the associated molecular pattern (DAMP) and induce immune responses and clinical cell injury mtDAMPs that cause increased urine protein in mice, resulting in damage to proteinuria and kidney [154].

CONCLUSION

Proteinuria, blood pressure, dipstick test, RAS, adipsin, SCR, ACR, and uric acid are biomarkers in PE diagnosis. Increased apoptosis, CCR necrosis, and syncytiolophoblast may compromise placental function, including nutrient transport and cause increased shedding of extracellular vesicle syncytiolophoblast (STBEV) so that compounds and antioxidant and antiapoptotic drugs are needed. MicroRNA in PE as major regulators in the stability of gene expression involved in cell proliferation and apoptosis. Liver and kidney disease in PE women have a high risk of pregnancy disorder, although until now no reports of maternal death, the birth of premature infants or neonatal death.

AKNOWLEDGEMENT

We are grateful to Directorate of Research and Community Service, Directorate General of Research and Development, Ministry of Research, Technology, and Higher Education in accordance with research and community service funding agreement for budgeting year 2018 (Fund of the research post-graduate team 1) to publish our journal to get Master of Biology (MSI).
 AUTHORS’ CONTRIBUTION
Putri Cahaya Situmorang undertook the most part during preparation of manuscript and Sjafiruddin Ilyas acted as corresponding author with responsibility to review the content and English grammar.

CONFLICTS OF INTEREST
The authors have declared no conflicts of interest.

REFERENCES
1. Alrahmani L, Willrich MV. The Complement Alternative Pathway and Preeclampsia. Current Hypertension Reports; 2018.
2. Correa PJ, Palmeiro Y, Soto MJ, Ugarte C, Illanes SE. Hypertension in pregnancy etiopathogenesis, prediction, and prevention of preeclampsia. Hypertens Pregnancy 2016;35:3-280-94.
3. Ishidou N, Matsuo H, Murakoshi H, Laouz-Fernandez JB, Samoto T, Maruo T, et al. Quantitation of Bel-2 oncogenes in cultures lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method. Haematologica 1995;80:495-504.
4. Allen AM, Kim WR, Larson JJ, Rosedahl JK, Yawn BP, McKeon K, et al. The epidemiology of liver diseases unique to pregnancy in a US community: A Population-based study. Clin Gastroenterol Hepatol 2016;14:287-940.
5. Rajakumar A, Ceresa AS, Rana S, Zengeller Z, Edmunds L, Jeeyabal A, et al. Transcriptional active syncytial aggregates in the maternal circulation may contribute to circulating soluble flt-like tyrosine kinase 1 in preeclampsia. Hypertension 2012;59:256-64.
6. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoposis in preeclampsia. Obstet Gynecol 2000;96:271-6.
7. Prakash J, Vohra R, Pandey LK, Niwas SS, Behura SK, Singh U, et al. Spectrum of kidney diseases in patients with preeclampsia-eclampsia. J Assoc Physicians India 2010;58:543-6.
8. Bhide A, Rana R, Dhavikar M, Amudio-Hernandez M, Deshpande D, Caric V, et al. The value of the urine protein:creatinine ratio for the detection of significant proteinuria in women with suspected preeclampsia. Acta Obstet Gynecol Scand 2015;94:542-6.
9. Sinha R, Bhushan I. Study of urinary calcium/creatinine ratio (crr) in a spot sample of urine for early prediction of preeclampsia. J Dent Med Sci 2016;15:1-6.
10. Elia EG, Robb AO, Hemmings K, Price MJ, Riley RD, French-Constant A, et al. Is the first urinary albumin/creatinine ratio (ACR) in women with suspected preeclampsia a prognostic factor for maternal and neonatal adverse outcome? A retrospective cohort study. Acta Obstet Gynecol Scand 2017;96:580-8.
11. Sarno I, Maruotti GM, Saccone G, Sirico A, Mazzarelli RL, Martinelli P, et al. Pregnancy outcome in proteinuria-onset and hypertension-onset preeclampsia. Hypertens Pregnancy 2015;34:190-7.
12. Kazee FF, Nijaking FA, Kengne AP, Ashuntantang G, Mbu R, Halle MP, et al. Post-partum trend in blood pressure levels, renal function and proteinuria in women with severe preeclampsia and eclampsia in sub-saharan africa: A 6-months cohort study. BMC Pregnancy Childbirth 2014;14:134.
13. Dong X, Gou W, Li C, Wu M, Han Z, Li X, et al. Proteinuria in preeclampsia: Not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy hypertens. Int J Women’s Cardiovasc Health 2017;9:6-60.
14. Tayyar AT, Ayar K, Kozali S, Karakus R, Karakus S, Yüksel IT, et al. Maternal cytoglobin (CYGB) serum levels in normal and preeclamptic pregnancies. J Matern Fetal Neonatal Med 2018;7:1-5.
15. Schmella MJ, Clifton RG, Althouse AD, Roberts JM. Uric acid determination in gestational hypertension: Is it as effective a delineator of risk as proteinuria in high-risk women? Reprod Sci 2015;22:1212-9.
16. Chen Q, Lau S, Tong M, Wei J, Shen F, Zhao J, et al. Serum uric acid may not be involved in the development of preeclampsia. J Hum Hypertens 2016;30:136-40.
17. Mohanty BP, Mahanty A, Mitra T. Heat shock proteins in stress in teleosts. Regul Heat Shock Protein Response 2018;13:71-94.
18. Liu F, He M, Yang M, Fan Y, Chen Y, Xia X, et al. Alteration of heat shock protein 20 expression in preeclamptic patients and its effect in vascular and coagulation function. Front Med 2018; doi: 10.1007/s11684-017-0576-x.
19. Schotet GE, Komeni O, Sadeh-Mestechkin D, Pomeranz M, Fishman A, Drucker L, et al. Heat shock protein-27 (HSP27) regulates Lif and s11684-017-0576-x.
20. Dvorakova L, Ivanova K, Krofa L, Hromadnikova I. Expression profile of heat shock proteins in placental tissues of patients with preterm prelabor rupture of membranes and spontaneous preterm labor with intact membranes. Am J Reprod Immunol 2017;78:4.
21. Abdulsid A, Lyall F. Heat shock protein 27 expression is spatially distributed in human placenta and selectively regulated during preeclampsia. J Reprod Immunol 2014;101-102:99-95.
22. Saghafi N, Pourali N, Ghavami Ghanbarabadi V, Mirzamjari F, Mirteimouri M. Serum heat shock protein 70 in preeclampsia and normal pregnancy: A systematic review and meta-analysis. Int J Reprod Biomed (Yazd) 2018;16:1-8.
23. Honsawek S, Udomsirinprasert W, Jaritathanomrak N, Chongsrisawat V, Povorawyan Y. Elevated serum heat shock protein 70 and liver stiffness reflect hepatic dysfunction and severity in postoperative biliary atresia. Pediatr Surg Int 2017;33:893-9.
24. Lai H, Liu H. Expression and meaning analysis of HIF-1α and HSP70 in preeclampsia. Biomed Res 2018:29:1240-3.
25. Ozaydin T, Sur E, Ozmurur Y, Celik I, Ulusik D. Immunohistochemical distribution of heat shock protein 70 and proliferating cell nuclear antigen in mouse placenta at different gestational stages. Microscopy Res Tech 2016;257:251-7.
42. Radons J. The human HSP70 family of chaperones: Where do we stand? Cell Stress Chromosom 2016;21:379-404.
43. Garamvölgyi Z, Pröhaska Z, Rigó J Jr. Kecskeméti A, Molvarec A. Increased circulating heat shock protein 70 (HSP70) levels in gestational diabetes mellitus: A pilot study. Cell Stress Chromosom 2015;20:575-81.
44. Hosseinie A, Dolati S, Hashemi V, Yousefi MA. Regulatory T and T helper 17 cells: Their roles in preeclampsia. J Cell Physiol 2018;1:1-13.
45. Quinn KH, Lacourcière DY, Cui L, Bui J, Parast MM. The unique pathophysiology of early-onset severe preeclampsia: Role of decidual T regulatory cells. J Reprod Immunol 2011;91:76-82.
46. Kong X, Kong J, Zhang Y, Fong W, Zhu T. Expression and significance of dendraritic cells and d17/Treg in serum and placental tissues of patients with intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2018;31:901-6.
47. Yang X, Zhang J, Ding Y. Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia. Medicine (Baltimore) 2017;96:e6509.
48. Lumbaranja SN, Junitasari R, Pasaribu HP. Differences of serum interleukin-6 levels in normotensive and preeclampsia women. IOP Conf Ser Earth Environ Sci 2018;25:104.
49. Rojas E, Rodríguez-Molina D, Bremmy L, Prima NF, Anita DA, Sofie RK, Debbie S, Garrabou G, Hernández AS, Catalán García M, Morén C, Tobías E, Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Obstet Invest 2011;71:250-5.
50. Afroz SH, Kalagiri RR, Reyes M, Zimmerman JD, Beeram MR, Pramatirta AY, Bremmy L, Prima NF, Anita DA, Sofie RK, Debbie S, Garamvölgyi Z, Prohászka Z, Rigó J Jr, Kecskeméti A, Molvarec A. Placental hypoxia developed during preeclampsia
51. Lu M, Piao L, Chen CP, Wu X, Yeh CC, Masch R, Huebner H, Knoerr B, Betzler A, Hartner A, Kehl S, Baier F, Hernandez A, Meza R, Zekic S, Prusac IK, Zegarac L, Roje D. Apoptosis, proliferation and fas ligand expression in placental trophoblast from pregnancies complicated by HELLP syndrome or pre-eclampsia. Acta Obstet Gynecol Scand 2011;90:1157-63.
52. Shem F, Wei J, Snowise S, De Sousa J, Stone P, Viall C, et al. Trophoblast debris extruded from preclamptic placenta activates endothelial cells: A mechanism by which the placenta communicates with the maternal endothelium. Placenta 2012;33:839-47.
53. Güzcler C, Uzerman NT, Dekker LJ, Derks P, Joore J, van Dijk E, et al. Multiple reaction monitoring assay for pre-eclampsia related calcineurin peptides in formalin fixed paraffin embedded placenta. J Proteome Res 2011;10:3274-82.
54. Longtine MS, Chen B, Obido AO, Zhong Y, Nelson DM. Caspase-mediated apoptosis of trophoblasts in term human placental villi is restricted to cytotrophoblasts and absent from the multinucleated syncytiotrophoblast. Reproduction 2012;143:107-21.
55. Zhou Y, Gormley MJ, Huikpati KM, Kapidize M, Stolyarov Y, Feng V, et al. Reversal of gene expression in human placental cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest 2013;123:2862 72.
56. Sankar KD, Bhanu PS, Kiran S, Ramakrishna BA, Shanthi V. Vasculosynaptic membrane in relation to synecytial knots complicates the placenta in preeclampsia: A histomorphometrical study. Anaerobics Cellulose 2012;45:86-91.
57. Ogunleye O, Campo B, Herrera D, Post Uiterweer ED, Conrad KP. Relaxin confers cytotrophoblast protection from hypoxia-reoxygenation injury through the phophatidylinositol 3-kinase-akt/protein kinase B cell survival pathway. Am J Physiol Regul Integr Comp Physiol 2017;312:R559-R568.
58. Tanetta D, Maslukaite I, Vatisl M, Redman C, Sargent I. Update of preeclampsia derived extracellular vesicles in normal pregnancy and preeclampsia. J Reprod Immunol 2017;119:98-106.
59. Conrad KP, Stillman IE, Lindheimer MD. The Kidney in Normal Pregnancy and Preeclampsia.4th ed. San Diego: Elsevier Inc.; 2015.
60. Cornelis T, Oudotay A, Keuen J, Hladunewich M. The kidney in normal pregnancy and preeclampsia. Semin Nephrol 2011;31:4-14.
61. Tian X, Ma S, Wang Y, Hou L, Shi Y, Yao M, et al. Effects of placental ischemia are attenuated by 1,25-dihydroxyvitamin D treatment and associated with reduced apoptosis and increased autophagy. DNA Cell Biol 2016;35:59-70.
62. Chen B, Tuuli MG, Longtime MS, Shin JS, Lawrence R, Inder T, et al. Pomegranate juice and punicagalic attenuate oxidative stress and apoptosis in pre-eclamptic placental trophoblasts. Am J Physiol Endocrinol Metab 2012;302:E1142-52.
63. Kavitha V, Srinivas B, Mvln RK, Shashikanth P. Assessment Of placental oxidative stress parameters in normal pre-eclamptic and normal pregnant women. Asian J Pharm Clin Res, Vol 11, Isse 11, 2018, 21-28
64. Guo M, Zhao X, Yuan X, Li P. Elevated microRNA-34a contributes to reduced apoptosis and increased autophagy in placental tissue in pregnancy-related complications. DNA Cell Biol 2015;34:437-57.
65. El-sonbati AZ, El-baz RA, Saad EA, El-zekred AS. Vascular endothelial growth factor levels in preclampsia maternal serum-induced placental trophoblast cell line. Acta Pathol 2016;186:1258-66.
66. Harradon G, Hernández AS, Catalán García M, Morén C, Tobías E, Córdoba S, et al. Molecular basis of reduced birth weight in smoking pregnant women: Mitochondrial dysfunction and apoptosis. Addict Biol 2016;21:159-70.
67. Pramantara AV, Bremmy L, Prima NF, Anita DA, Sofie RK, Debbie S, et al. Effects of low dose aspirin on caspase 3, int-l Raiders and apoptotic index levels in placenta maternal serum-induced placental trophoblast cell line in vitro. Int J PharmTech Res 2016;9:47-53.
68. Tannetta D, Masliukaite I, Vatisl M, Redman C, Sargent I. Update of placental oxidative stress parameters in pre-eclamptic and normal pregnant women. Acta Obstet Gynecol Scand 2018;97:E1370-9.
69. Gao Q, Zhu X, Yuan X, Li P. Elevated microRNA-34a results in trophoblast cell apoptosis in preeclampsia by targeting BCL-2. J Hum Hypertens 2017;31:815-20.
70. Arman DR, Fritz R, Kilburn BA, Kim YM, Nien JK, Mahile NJ, et al. Reduced expression of the epidermal growth factor signalling system in preeclampsia. Placenta 2015;36:270-8.
71. Zhang Z, Zhang L, Zhang L, Jia L, Wang P, Gao Y, et al. Association of wnt2 and sFRP4 expression in the third trimester placenta in women with severe preeclampsia. Reprod Sci 2013;20:981-9.
72. X Li. Contents of Wnt10b -catenin signaling pathway-related molecules in the placenta placenta tissue and their correlation with the trophocyte apoptosis. J Hainan Univ 2017;23:83-6.
73. Derzsy Z, Pröhaska Z, Rigó J Jr. Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Med 2010;14:1500-6.
74. Gao Q, Zhu X, Chen J, Mao C, Zhang L, Xu Z, et al. Upregulation of P53 promoted G1 arrest and apoptosis in human umbilical cord vein endothelial cells from preeclampsia. J Hypertens 2016;34:1380-8.
75. Tannetta D, Sargent I. Placental disease and the maternal syndrome of preeclampsia: Missing links? Curr Hypertens Rep 2013;15:590-9.
76. Yu L, Li D, Liao QP, Yang HX, Cao B, Fu G, et al. High levels of activin A detected in preeclamptic placenta induce trophoblast cell apoptosis by promoting nodal signaling. J Clin Endocrinol Metab 2012;97:E1370-9.
77. Yu J, Guo X, Chen R, Feng L. Downregulation of mitofusin 2 in placenta is related to preeclampsia. Bio Med Res Int 2016;2016:8.
90. Vishnyakova PA, Maria AV, NadezhdA VT, Maria VM, Daria VT, Olga V, et al. Mitochondrial role in adaptive response to stress conditions in preeclampsia. Nat Publ Gr 2016;2016:1-9.

91. Yong HJ, Mahn V, Schmer A, Breunecke SP, Moses EK. Genetic approaches in preeclampsia. Methods Mol Biol 2018;1710:53-72.

92. Muralimahanaran S, Maloyan A, Myatt L. Evidence of sexual dimorphism in the placental function with severe preeclampsia. Placenta 2013;34:1183-9.

93. Ma Y, Kong J, Li Q, Lu YV, Hong MN, Zhang Y, et al. Complement 5a-mediated trophoblast dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med 2018;22:1034-46.

94. Shi Z, Hou W, Hua X, Wang Z. Overexpression of calreticulin in pre-eclampsia. Cell Biochem Biophys 2012;63:183-9.

95. Guller S, Tang Z, Ma YV, Di Santo S, Sager R, Schneider H, et al. Protein composition of microparticles shed from human placenta during placental perfusion: Potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta 2011;32:63-9.

96. Baig S, Kothandaraman N, Manikannd J, Rong L, Ee KH, Hill J, et al. Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics 2014;11:40.

97. Wang W, Parchim NF, Irinyai T, Luo R, Zhao C, Liu C, et al. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension 2014;63:595-606.

98. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011;18:145-50.

99. Enquobahrie DA, Abetew DF, Sorrensen TK, Willoughby D, Chidambaram K, Williams MA, et al. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2011;204:178.e12-21.

100. Muralimahanaran S, Maloyan A, Mele J, Guo C, Myatt LG, Myatt L, et al. mir-210 modulates mitochondrial respiration in placenta with APOL1-G0 or APOL1-G2 transgenic models. Proteomics 2014;14:108.

101. Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, et al. Overexpression of calreticulin in pre-eclampsia as shown by transient elastography. Hypertens Pregnancy 2015;34:94-6.

102. Bremer L, Schramm C, Tiegs G. Immunology of hepatic diseases in pregnancies complicated by preeclampsia and fetal growth restriction. Eur J Gastroenterol Hepatol 2015;27:417-23.

103. Tsai HM, Kuo E. From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol 2016;127:907-10.

104. Panda R, Mondal H. Liver function tests in elderly gravidae presenting with preeclampsia. J Obstet Gynaecol India 2016;66:129-35.

105. Karakus S, Bozoklu Akkar O, Yildiz C, Sancaekdar E, Cetin M, Cetin A, et al. Serum levels of E1-F, M30, and angiopeptin-1 and -2 in HELLP syndrome and preeclampsia compared to controls. Arch Gynecol Obstet 2016;293:351-9.

106. Mohamed S, Abdelgadir N, Eldeen N, Mohammed A. Estimation of plasma d-dimer levels in sudanese women with preeclampsia. Sci Res 2013;4:61.

107. Jonas H. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int 2015;10:1-7.

108. Meng J, Wang S, Wu Y, Li H, Jiang J, Wang X, et al. Prenatal predictors in postpartum recovery for acute fatty liver of pregnancy: Experiences at a tertiary referral center. Arch Gynecol Obstet 2016;293:1185-91.

109. Qu BG, Wang H, Jia YG, Su JL, Wang ZD, Wang YF, et al. Changes in tumor necrosis factor-α, heat shock protein 70, malondialdehyde, and superoxide dismutase in patients with different severities of alcoholic fatty liver disease: A prospective observational study. Medicine (Baltimore) 2015;94:e643.

110. Wikström Shemer EA, Stephansson O, Thorsell M, Ludvigsson JF, Marschall HU, et al. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. J Hepatol 2015;63:456-61.

111. Solanke D, Rath D, Pandit M, Patel P, Phadke A, Sawant P, et al. Etiology, clinical profile, and outcome of liver disease in pregnancy with predictors of maternal mortality: A prospective study from western india. Indian J Gastroenterol 2016;35:450-8.

112. Wilder J, Chang S, Cardona D, Patel K, Brady C. Acute liver failure in the setting of herpes simplex virus and coexistent acute fatty liver of pregnancy. Case Reports Clin Pathol 2015;2:89-94.

113. Puljic A, Salati J, Doss A, Caughey AB. Outcomes of pregnancies complicated by liver cirrhosis, portal hypertension, or esophageal varices. J Matern Fetal Neonatal Med 2016;29:506-9.

114. Tang YM, Wang JP, Bao WM, Yang JH, Ma LK, Yang J, et al. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med 2015;36:377-85.

115. Yoshimura H, Mayama Y, Ukai M, Tano S, Kishigami Y, Oguchi H, et al. Fulminant liver failure resulting from massive hepatic infarction associated with hemolysis, elevated liver enzymes, and low platelets syndrome. J Obstet Gynecol Res 2016;42:1375-8.

116. Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). AJSF position paper on liver transplantation and pregnancy: Women in hepatology group, italian association for the study of the liver (AISF). Dig Liver Dis 2016;48:860-8.

117. Lopes van Balen VA, Spaan JJ, Cornelis T, Spaanderman MEA. Prevalence of chronic kidney disease after preeclampsia. J Nephrol 2017;30:403-9.

118. Turner RJ, Bloemenkamp KW, Penning ME, Bruijn JA, Baelde HJ. From glomerular endothelium to podocyte pathology in preeclampsia: A Paradigm shift. Curr Hypertens Rep 2015;17:54.

119. Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocyturia, and eosinophilic casts in women with preeclampsia. J Am Physiol Renal Physiol 2012;302:F1084-9.

120. Furuta I, Zhai T, Ishikawa S, Umazume T, Nakagawa K, Yamada T, et al. Association between nephrinuria, podocyturia, and proteinuria in pregnancies complicated by preeclampsia. J Obstet Gynecol Obstet Gynecol Res 2013;43:34-41.

121. Bruggeman LA, Wu Z, Luo L, Madhavan SM, Konieczkowski M, Dawaz PE, et al. APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. J Am Soc Nephrol 2016;27:3600-10.

122. Unverdi S, Ceri M, Unverdi H, Yilmaz R, Akcay A, Duranay M. Postpartum persistent proteinuria after preeclampsia: A single-center
experience. Wien Klin Wochenschr 2013;125:91-5.

136. Al-hakeim HK, Ali R, Ali M. Proteinuria as the most relevant parameter affecting fetuin-a levels in preeclampsia. Acta Fac Med Naisensis 2015;52:267-77.

137. Piccoli GB, Cabiddu G, Castellino S, Gernone G, Santoro D, Moroni G, et al. A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: The italian study group on kidney and pregnancy. J Nephrol 2017;30:307-17.

138. Duvekot JJ. Re: Maternal venous doppler characteristics are abnormal in pre-eclampsia but not in gestational hypertension. W. Gyselaers, A. Staelens, T. Mesens, K. Tomsin, J. Oben, S. Vonck, L. Verresen and G. Molenberghs. Ultrasound obstet gynecol 2015; 45: 421-426. Ultrasound Obstet Gynecol 2015;45:374-5.

139. Masuyama H, Nobumoto E, Okimoto N, Inoue S, Segawa T, Hiramatsu Y, et al. Superimposed preeclampsia in women with chronic kidney disease. Gynecol Obstet Invest 2012;25:1090-5.

140. Garg AX, Nevis IF, McArthur E, Sontrop JM, Koval JJ, Lam NN, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med 2015;372:124-33.

141. Siribamrungwong M, Chinudomwong P. Relation between acute kidney injury and pregnancy-related factors. J Acute Dis 2016;5:22-8.

142. Nielsen LH, Jensen BL, Fuglsang J, Andersen LLT, Jensen DM, Jørgensen JS, et al. Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients. J Am Soc Hypertens 2018;12:97-107.

143. Simonazzi G, Capelli I, Curti A, Comai G, Rizzo N, La Manna G, et al. Serum and urinary neutrophil gelatinase-associated lipocalin monitoring in normal pregnancy versus pregnancies complicated by pre-eclampsia. J Am Soc Hypertens 2015;29:117-21.

144. Ding W, Wang B, Zhang M, Gu Y. Tempol, a superoxide dismutase-mimetic drug, ameliorates progression of renal disease in CKD mice. Cell Physiol Biochem 2015;36:2170-82.

145. Attini R, Leone F, Montersino B, Fassio F, Minelli F, Colla L, et al. Pregnancy, proteinuria, plant-based supplemented diets and focal segmental glomerulosclerosis: A Report on three cases and critical appraisal of the literature. Nutrient 2017;9(7).

146. Zhang Y, Zhao C, Wei Y, Yang S, Cui C, Yang J, et al. Increased circulating microparticles in women with preeclampsia. Int J Lab Hematol 2018;40:352-8.

147. Codsi E, Garovic VD, Gonzalez-Suarez ML, Milic N, Borowski KS, Rose CH, et al. Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. Am J Physiol Regul Integr Comp Physiol 2017;312:R773-R778.

148. Wang Y, Gu Y, Loyd S, Jia X, Groome LJ. Increased urinary levels of podocyte glycoproteins, matrix metallopeptidases, inflammatory cytokines, and kidney injury biomarkers in women with preeclampsia. Am J Physiol Renal Physiol 2015;309:F1009-17.

149. Rolfo A, Parisi S, Ferraresi M, Todros T, Giorgina B. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2012;83:177-81.

150. Xiao J, Niu J, Ye X, Yu Q, Gu Y. Combined biomarkers evaluation for diagnosing kidney injury in preeclampsia. Hypertens Pregnancy 2013;32:439-49.

151. Zhang Y, Liu F, Chen S, Zhong M. Low-molecular-weight heparin protects kidney through an anti-apoptotic mechanism in a rat pre-eclamptic model. Eur J Obstet Gynecol Reprod Biol 2015;188:51-5.

152. Liu W, Qiao F, Liu H, Gong X, Shi X, Li Y, et al. Low molecular weight heparin improves proteinuria in rats with L-NAME induced preeclampsia by decreasing the expression of nephrin, but not podocin. Hypertens Pregnancy 2015;34:24-35.

153. He J, Lu Y, Xia H, Liang Y, Wang X, Bao W, et al. Circulating mitochondrial DAMPs are not effective inducers of proteinuria and kidney injury in rodents. PLoS One 2015;10:e0124469.